These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37487406)

  • 1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
    Rivera-Caravaca JM; Anguita Sanchez M; Sanmartín Fernández M; Rafols C; Barón-Esquivias G; Arribas Ynsaurriaga F; Freixa-Pamias R; Lekuona Goya I; Vázquez Rodríguez JM; Pérez-Cabeza AI; Cosín-Sales J; Ureña Montilla I; Álvarez-Vieitez Blanco A; Marín F
    Am J Cardiol; 2023 Sep; 203():122-127. PubMed ID: 37487406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.
    Anguita Sánchez M; Marín F; Masjuan J; Cosín-Sales J; Vázquez Rodríguez JM; Barrios V; Barón-Esquivias G; Lekuona I; Pérez-Cabeza AI; Freixa-Pamias R; Parra Jimenez FJ; Monzer Khanji Khatib M; Rafols Priu C; Sanmartín Fernández M
    Cardiol J; 2022; 29(6):936-947. PubMed ID: 36200548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
    Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
    Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
    Sanmartín Fernández M; Anguita Sánchez M; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Esteve-Pastor MA; Freixa-Pamias R; Lekuona I; Pérez-Cabeza AI; Ureña I; Vázquez Rodríguez JM; Rafols Priu C; Marin F
    Cardiol J; 2022; 29(4):601-609. PubMed ID: 35621092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.
    López-Gálvez R; Rivera-Caravaca JM; Anguita Sánchez M; Sanmartín Fernández M; Rafols C; Pérez-Cabeza AI; Barón Esquivias G; Lekuona Goya I; Vázquez Rodríguez JM; Cosín Sales J; Arribas Ynsaurriaga F; Barrios V; Freixa-Pamias R; Marín F
    Eur J Clin Invest; 2022 Sep; 52(9):e13788. PubMed ID: 35395094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
    Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.
    Patti G; Pecen L; Casalnuovo G; Manu MC; Kirchhof P; De Caterina R
    Clin Res Cardiol; 2023 Nov; 112(11):1517-1528. PubMed ID: 35976428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
    Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
    JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America.
    Martínez CAA; Lanas F; Radaideh G; Kharabsheh SM; Lambelet M; Viaud MAL; Ziadeh NS; Turpie AGG;
    Egypt Heart J; 2018 Dec; 70(4):307-313. PubMed ID: 30591748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?
    Lehtola H; Hartikainen J; Hartikainen P; Kiviniemi T; Nuotio I; Palomäki A; Ylitalo A; Airaksinen KEJ; Mustonen P
    Clin Cardiol; 2018 May; 41(5):608-614. PubMed ID: 29745996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry).
    Abe M; Ogawa H; Ishii M; Masunaga N; Esato M; Chun YH; Tsuji H; Wada H; Hasegawa K; Lip GY; Akao M
    Am J Cardiol; 2017 Apr; 119(8):1229-1237. PubMed ID: 28219663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.